ES2133410T3 - Derivados sustituidos de la tiazolidindiona. - Google Patents

Derivados sustituidos de la tiazolidindiona.

Info

Publication number
ES2133410T3
ES2133410T3 ES93919489T ES93919489T ES2133410T3 ES 2133410 T3 ES2133410 T3 ES 2133410T3 ES 93919489 T ES93919489 T ES 93919489T ES 93919489 T ES93919489 T ES 93919489T ES 2133410 T3 ES2133410 T3 ES 2133410T3
Authority
ES
Spain
Prior art keywords
group
compound
replaced
substituents
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93919489T
Other languages
English (en)
Inventor
Colin Ripley Pool
Robin Sherwood Roman
Malcolm David Brighwell
Alan William Tremper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10721461&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2133410(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of ES2133410T3 publication Critical patent/ES2133410T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN COMPUESTO DE FORMULA (I) DE UNA FORMA TAUTOMERICA DEL MISMO Y/O UN SOLVATO FARMACEUTICAMENTE ACEPTABLE DEL MISMO, DONDE: R1 REPRESENTA UN ATOMO DE HIDROGENO, UN GRUPO ALQUILO, UN GRUPO ACILO, UN GRUPO ARALQUILO, DONDE LA MITAD ARILO PUEDE SER SUSTITUIDA O NO SUSTITUIDA, O UN GRUPO ARILO SUSTITUIDO O NO SUSTITUIDO; A1 REPRESENTA HIDROGENO O 1 A 4 SUSTITUYENTES OPCIONALES, SELECCIONADOS DEL GRUPO FORMADO POR: ALQUILO, ALCOXI, ARILO Y HALOGENO, O A1 REPRESENTA DOS SUSTITUYENTES SOBRE ATOMOS ADYACENTES DE CARBONO, CUYOS SUSTITUYENTES, JUNTAMENTE CON LOS ATOMOS DE CARBONO A LOS CUALES ESTAN UNIDOS, FORMAN UN GRUPO ARILO SUSTITUIDO O NO SUSTITUIDO; A2 REPRESENTA UN ANILLO DE BENCENO, QUE TIENE DE 1 A 3 SUSTITUYENTES OPCIONALES; Y M REPRESENTA UN CONTRAION; UN PROCESO PARA PREPARAR TAL CLASE DE COMPUESTO, UNA COMPOSICION FARMACEUTICA COMPRENDIENDO TAL CLASE DE COMPUESTO, Y EL USO DE TAL CLASE DE COMPUESTO Y COMPOSICION EN MEDICINA.
ES93919489T 1992-09-05 1993-09-01 Derivados sustituidos de la tiazolidindiona. Expired - Lifetime ES2133410T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929218830A GB9218830D0 (en) 1992-09-05 1992-09-05 Novel compounds

Publications (1)

Publication Number Publication Date
ES2133410T3 true ES2133410T3 (es) 1999-09-16

Family

ID=10721461

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93919489T Expired - Lifetime ES2133410T3 (es) 1992-09-05 1993-09-01 Derivados sustituidos de la tiazolidindiona.

Country Status (38)

Country Link
US (1) US5910592A (es)
EP (2) EP0658161B1 (es)
JP (5) JP2828777B2 (es)
KR (3) KR20030097596A (es)
CN (4) CN1040323C (es)
AP (1) AP513A (es)
AT (1) ATE182147T1 (es)
AU (1) AU674880B2 (es)
BR (1) BR1100916A (es)
CA (2) CA2273147A1 (es)
CY (1) CY2138B1 (es)
CZ (2) CZ287473B6 (es)
DE (2) DE69325658T2 (es)
DK (1) DK0658161T3 (es)
ES (1) ES2133410T3 (es)
FI (2) FI106263B (es)
GB (1) GB9218830D0 (es)
GR (1) GR3030794T3 (es)
HK (1) HK1012363A1 (es)
HU (2) HU0500355D0 (es)
IL (1) IL106904A (es)
LU (1) LU90712I2 (es)
MA (1) MA22970A1 (es)
MX (1) MX9305397A (es)
MY (1) MY111190A (es)
NL (1) NL300035I2 (es)
NO (4) NO303016B1 (es)
NZ (1) NZ255505A (es)
PL (1) PL173725B1 (es)
RU (3) RU2128179C1 (es)
SA (1) SA93140245B1 (es)
SG (2) SG83747A1 (es)
SI (1) SI9300452B (es)
SK (1) SK280777B6 (es)
TW (1) TW385309B (es)
UA (1) UA41901C2 (es)
WO (1) WO1994005659A1 (es)
ZA (1) ZA936509B (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5889032A (en) * 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
AU744518B2 (en) * 1996-07-01 2002-02-28 Dr. Reddy's Laboratories Limited Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
WO1998002159A1 (en) * 1996-07-12 1998-01-22 Smithkline Beecham Plc Novel treatment of leptine resistance
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
CA2294582C (en) * 1997-06-18 2008-02-12 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and metformin
UA67743C2 (uk) * 1997-06-18 2004-07-15 Смітклайн Бічам П.Л.С. Фармацевтична композиція, що містить тіазолідиндіон і сульфонілсечовину, для лікування діабету
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9723295D0 (en) * 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
AU770817B2 (en) * 1997-12-16 2004-03-04 Smithkline Beecham Plc 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,dione,maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
AU774613B2 (en) * 1997-12-16 2004-07-01 Smithkline Beecham Plc Hydrate of 5-(4-(2- (N-methyl-N- (2-pyridil)amino) ethoxy)benzyl) thiazolidine-2,4-dione maleic acid salt
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
HUP0103199A3 (en) * 1998-07-21 2002-08-28 Smithkline Beecham Lab Use of glucose uptake enhancer for reducing apoptosis
CA2351058A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
AR023699A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Corp Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9909075D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
IL146115A0 (en) * 1999-04-23 2002-07-25 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
DK1284268T3 (da) * 1999-04-23 2008-04-28 Smithkline Beecham Plc Fremstilling af en polymorf form af et thiazolidindionderivat
PT1173435E (pt) * 1999-04-23 2003-12-31 Smithkline Beecham Cork Ltd Polimorfo de 5-¬4-¬2-(n-metil-n-(2-piridil)-amino)-etoxi|benzil|tiazolidino-2,4-diona sal de acido maleico
CA2381976A1 (en) * 1999-08-17 2001-02-22 Michael Urquhart Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
GB0014006D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
MXPA02012619A (es) * 2000-06-16 2003-04-10 Smithkline Beecham Plc Tratamiento y prevencion de condiciones asociadas con resistencia a la insulina cardiaca.
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2005229687B2 (en) * 2000-08-04 2008-03-13 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
AU2005229688B2 (en) * 2000-08-04 2008-04-03 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019224D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021785D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel Pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
NZ525498A (en) * 2000-09-26 2004-11-26 Reddys Lab Ltd Dr Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
ATE337313T1 (de) * 2000-12-22 2006-09-15 Smithkline Beecham Plc 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy)benzyl)thiazolidin-2,4-dion mesylatsalz
WO2002051823A1 (en) 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Process for the preparation of rosiglitazone maleate
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
ATE349444T1 (de) * 2001-11-21 2007-01-15 Smithkline Beecham Plc 5-(4-(2-(n-methyl-n-(2- pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-di n-benzolsulfonat; prozess zu seiner herstellung; polymorphe i, ii und iii davon; und seine verwendung als pharmazeutischer wirkstoff
WO2003045947A1 (en) * 2001-11-21 2003-06-05 Smithkline Beecham P.L.C. Rosiglitazone edisylates and their use as antidiabetics
GB0129851D0 (en) * 2001-12-13 2002-01-30 Smithkline Beecham Plc Novel compounds
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
WO2003050116A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130510D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004062667A1 (en) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Amorphous form of rosiglitazone maleate and process for preparation thereof
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
WO2005058813A2 (en) * 2003-12-17 2005-06-30 Ranbaxy Laboratories Limited Thiodiazolidinedione, oxazolidinedione and diazolidinedione derivatives and their use as antidiabetic agents
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
WO2005073227A2 (en) * 2004-01-28 2005-08-11 Usv Limited A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
GB2421240A (en) * 2004-12-14 2006-06-21 Sandoz Ag Phosphoric acid salt of rosiglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
CZ2004844A3 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
KR100749219B1 (ko) * 2006-03-15 2007-08-13 건일제약 주식회사 신규한 로지글리타존 옥살산염, 이의 제조방법, 및 이를포함하는 약제학적 조성물
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101511364B (zh) 2006-09-07 2012-08-15 奈科明有限责任公司 用于糖尿病的治疗组合
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP1967182A1 (en) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a salt of rosigliatazone
CA2690004C (en) 2007-06-04 2018-01-23 Ben-Gurion University Of The Negev Research And Development Authority Tri-aryl compounds and compositions comprising the same
CN101167726B (zh) * 2007-10-16 2011-05-18 宁夏康亚药业有限公司 马来酸罗格列酮分散片及其制备方法
PL384446A1 (pl) * 2008-02-12 2009-08-17 Adamed Spółka Z Ograniczoną Odpowiedzialnością Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
CN102532122B (zh) * 2010-12-29 2015-12-02 开封制药(集团)有限公司 酒石酸罗格列酮的制备方法
JP6657101B2 (ja) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ 糖尿病及びそれから生じる疾患合併症の治療のための化合物
WO2016071727A1 (en) 2014-11-04 2016-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
IT201800002630A1 (it) * 2018-02-13 2019-08-13 Giuliani Spa Composizione per la prevenzione e il trattamento dei disturbi della crescita dei capelli

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197297A (en) * 1976-11-17 1980-04-08 Smithkline Corporation 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines
US4405211A (en) * 1980-07-29 1983-09-20 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Liquid crystal compositions with pleochroic anthraquinone dyes
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5039687A (en) * 1985-12-04 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamine compounds having enhancing activity
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
EP0658161A1 (en) 1995-06-21
TW385309B (en) 2000-03-21
SI9300452A (en) 1994-06-30
JP2828777B2 (ja) 1998-11-25
KR20080081099A (ko) 2008-09-05
IL106904A0 (en) 1993-12-28
EP0960883A1 (en) 1999-12-01
SG83747A1 (en) 2001-10-16
GB9218830D0 (en) 1992-10-21
CN1101911A (zh) 1995-04-26
CA2143849C (en) 2000-04-25
CZ287473B6 (en) 2000-12-13
WO1994005659A1 (en) 1994-03-17
JPH08501095A (ja) 1996-02-06
AP9300562A0 (en) 1993-10-31
NO2001006I1 (no) 2001-04-30
CN1183413A (zh) 1998-06-03
CN1183275A (zh) 1998-06-03
RU95108329A (ru) 1996-12-20
NO2001005I2 (no) 2004-06-01
JP2002047288A (ja) 2002-02-12
CA2143849A1 (en) 1994-03-17
JPH11147885A (ja) 1999-06-02
PL307812A1 (en) 1995-06-26
ZA936509B (en) 1994-06-16
CN1040323C (zh) 1998-10-21
LU90712I2 (fr) 2001-03-12
FI982413A0 (fi) 1998-11-06
DE10199002I2 (de) 2001-12-13
RU2128179C1 (ru) 1999-03-27
PL173725B1 (pl) 1998-04-30
CN1063942C (zh) 2001-04-04
CN1051312C (zh) 2000-04-12
NL300035I2 (nl) 2001-07-02
CN1066939C (zh) 2001-06-13
NZ255505A (en) 1997-08-22
HU9500659D0 (en) 1995-04-28
SK27795A3 (en) 1995-08-09
JP2004359676A (ja) 2004-12-24
NL300035I1 (nl) 2001-03-01
SA93140245B1 (ar) 2005-10-15
MX9305397A (es) 1995-01-31
RU98117673A (ru) 2000-07-20
NO950852L (no) 1995-03-03
DE69325658T2 (de) 1999-12-30
GR3030794T3 (en) 1999-11-30
BR1100916A (pt) 2000-07-04
UA41901C2 (uk) 2001-10-15
MA22970A1 (fr) 1994-04-01
CY2138B1 (en) 2002-06-21
SI9300452B (sl) 2003-02-28
SG48302A1 (en) 1998-04-17
MY111190A (en) 1999-09-30
JP2008208142A (ja) 2008-09-11
DK0658161T3 (da) 1999-11-29
KR100371297B1 (ko) 2003-05-09
NO303016B1 (no) 1998-05-18
CA2273147A1 (en) 1994-03-17
AU4973093A (en) 1994-03-29
AP513A (en) 1996-07-30
NO974646D0 (no) 1997-10-08
IL106904A (en) 1997-09-30
RU98117628A (ru) 2000-08-20
FI951004A (fi) 1995-03-03
CZ56595A3 (en) 1995-11-15
KR950702982A (ko) 1995-08-23
DE69325658D1 (de) 1999-08-19
ATE182147T1 (de) 1999-07-15
KR20030097596A (ko) 2003-12-31
HK1012363A1 (en) 1999-07-30
FI982413A (fi) 1998-11-06
HUT72639A (en) 1996-05-28
FI106263B (fi) 2000-12-29
CZ290591B6 (cs) 2002-08-14
NO305802B1 (no) 1999-07-26
FI951004A0 (fi) 1995-03-03
CN1183276A (zh) 1998-06-03
NO950852D0 (no) 1995-03-03
SK280777B6 (sk) 2000-07-11
NO974646L (no) 1995-03-03
AU674880B2 (en) 1997-01-16
HU0500355D0 (en) 2005-05-30
HU224212B1 (hu) 2005-06-28
US5910592A (en) 1999-06-08
EP0658161B1 (en) 1999-07-14

Similar Documents

Publication Publication Date Title
ES2133410T3 (es) Derivados sustituidos de la tiazolidindiona.
MX9302088A (es) Derivados de alfa-tiocarbonilo y alfa-halocarbonilo, proceso para su preparacion y composicion farmaceutica que los comprende.
NL300034I2 (nl) Gesubstitueerde thiahzolidinedionderivaten.
AR210242A1 (es) Nuevos derivados sustituidos de 1-(1,2,4,triazolil-(1))-1-fenoxi-2-hidroxietano con propiedades fitofungicidas,composiciones fitofungicidas a base de los mismos y procedimientos para la produccion de dichos compuetos
ES2059491T3 (es) Derivados de indol con anillos condensados.
ES2134755T3 (es) Derivados de quinolina como antagonistas de leucotrieno d4, composiciones que contienen los mismos y procedimientos para su preparacion.
ES2096091T3 (es) Nuevas composiciones a base de derivados de la clase de los taxanos.
UY24555A1 (es) Nuevos compuestos
MX9303981A (es) Nuevos compuestos farmaceuticos, proceso para su preparacion y composicion farmaceutica que los contiene.
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
MX9302957A (es) Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
IT1145403B (it) Derivati di 1,2-diidro-2-osso-4-fenil-3-chinolin-carbonitrile dotati di proprieta' anti-infiammatorie
CO5130006A1 (es) Compuestos de pirazina
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR205894A1 (es) Nuevos derivados de 1-(1, 2, 4-triazolil - 1') - 2 - fenoxi - 4, 4 - dimetil - pentan - 3 - ona de propiedades fungicidas composiciones fungicidas a base de los mismos y procedimiento para la produccion de dichos compuestos
ES2119874T3 (es) Nuevos derivados de elipticina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
SE9003973D0 (sv) Glycerol, ett framstaellningsfoerfarande foer desamma samt terapeutiska kompositioner innehaallande dem
SE397523B (sv) Forfarande att framstella n-fenylpyrrolderivat med antiinflammatorisk och analgetisk verkan
SE7609985L (sv) Difenylaminderivat med rodenticid verkan, kompositioner innehallande desamma samt deras anvendning for bekempande av rattor och moss
KR850005433A (ko) 나프티리딘 및 피리도피리미딘 화합물의 제조방법
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
CO4650030A1 (es) Derivados de n-(benzotiazol-2-il) piperidina-1-etanamina, proceso para su preparacion y producto farmaceutico que los contiene
ES2060592T3 (es) Un tioester y su uso en la preparacion de composiciones farmaceuticas para el tratamiento de los sindromes de isquemia y reperfusion.
IT1114721B (it) Derivati di 3,3-dicloro-2-azetidinone ad attivita' anti-infiammatoria

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 658161

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: MALEATO DE ROSIGLITAZONA (AVANDIA)

Spc suppl protection certif: C200100004

Filing date: 20010101

SPCG Supplementary protection certificate granted

Free format text: MALEATO DE ROSIGLITAZONA (AVANDIA)

Spc suppl protection certif: C200100004

Filing date: 20010101

Expiry date: 20150711

Effective date: 20031106

Free format text: MALEATO DE ROSIGLITAZONA (AVANDIA).

Spc suppl protection certif: C200100004

Filing date: 20010101

Expiry date: 20150711

Effective date: 20031106